Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The methods of assessing the clinical relevance of a significant difference between antidepressants and placebo are discussed. The commonly used criteria of treatment effect and responder rates, as well as the percentage difference in responders between antidepressant and placebo, are critically reviewed and applied to assess the clinical relevance of the significant advantages reported in double-blind, randomized, controlled studies of escitalopram compared with other antidepressants. A significant advantage for escitalopram has been reported in randomized, double-blind, short-term studies compared with citalopram, paroxetine and duloxetine. The reported significant differences are clinically relevant based on a treatment effect difference of at least 2 points on the Montgomery and Asberg Depression Rating Scale as well as a significant advantage in the protocolled responder or remission analysis. The mean unadjusted treatment effect advantage for escitalopram compared with the antidepressants studied is 2.42 points on the Montgomery and Asberg Depression Rating Scale in the short-term treatment. Excluding one study that did not report short-term responder rates, there were significantly more responders on escitalopram (74%) than comparators (63%). Both of these measures demonstrate a clinically relevant difference in favour of escitalopram.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the observed 24.0 difference exceeded minimum clinically important difference thresholds reported in the literature (26,27).”
In the citing paper
“which is considered a clinically meaningful treatment difference (26,27) suggesting rapid onset of antidepressant efficacy.”
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Self-citationDevelopment of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456
Kennedy, S. H., Andersen, H. F., & Lam, R. W. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0615 · Cited by 216
Moore, N., Verdoux, H., & Fantino, B. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00002 · Cited by 188
Gorman, J. M., Korotzer, A., & Su, G. (2002) · CNS Spectrums · doi:10.1017/s1092852900028595 · Cited by 169
Which antidepressants have demonstrated superior efficacy? A review of the evidence
Montgomery, S. A., Baldwin, D. S., Blier, P., Fineberg, N. A., Kasper, S., Lader, M., Lam, R. W., Lépine, J.-P., Möller, H.-J., Nutt, D. J., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282eff7e0 · Cited by 165
Self-citationNierenberg, A. A., Greist, J. H., Mallinckrodt, C. H., Prakash, A., Sambunaris, A., Tollefson, G. D., & Wohlreich, M. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167453 · Cited by 131
Research works printed but not linked: 1
- Kennedy, 2006, J Psychiatry Neurosci, 31, 122
Cited by
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Taken together, results from meta-analyses suggest superiority of intravenous ketamine or esketamine when compared with second-generation antipsychotics (19, 143, 150, 151).”
ResultBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“Percentage of patients with response or remission is considered to be a meaningful measure of clinical relevance (Montgomery and Moller 2009).”
BackgroundSelf-citationFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000023 · Cited by 295
“…published evidence from preclinical in-vitro and in-vivo pharmacology studies (e.g. Sanchez and Meier, 1997) and clinical efficacy studies (Montgomery et al., 2007; Rao, 2007; Kasper et al., 2009b; Montgomery and Moller, 2009) that would support meaningful differences among SSRIs in their effects.”
BackgroundInfluentialSelf-citationAndersson, G., Hesser, H., Veilord, A., Svedling, L., Andersson, F., Sleman, O., Mauritzson, L., Sarkohi, A., Claesson, E., Zetterqvist, V., et al. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.08.022 · Cited by 195
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Augustine, C., Zhang, P., McQuade, R. D., Carson, W. H., Nyilas, M., Sanchez, R., et al. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09688 · Cited by 182
Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176
Thase, M. E., Youakim, J. M., Skuban, A., Hobart, M., Zhang, P., McQuade, R. D., Nyilas, M., Carson, W. H., Sanchez, R., & Eriksson, H. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09689 · Cited by 165
Thase, M. E., Mahableshwarkar, A. R., Dragheim, M., Loft, H., & Vieta, E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.007 · Cited by 162
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143
Self-citationMillan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Hengartner, M. P., & Plöderl, M. (2022) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2020-111600 · Cited by 114
Zhong, H., Haddjeri, N., & Sánchez, C. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2463-5 · Cited by 105
“2011; Montgomery and Moller 2009) and to paroxetine and duloxetine (Cipriani et al. 2009; Kasper et al. 2009a; Montgomery and Moller 2009).”
Koesters, M., Guaiana, G., Cipriani, A., Becker, T., & Barbui, C. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.120196 · Cited by 93
Baldwin, D. S., Florea, I., Jacobsen, P. L., Zhong, W., & Nomikos, G. G. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.07.015 · Cited by 93
Sambunaris, A., Bose, A., Gommoll, C. P., Chen, C., Greenberg, W. M., & Sheehan, D. V. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000060 · Cited by 90
Asnis, G. M., Bose, A., Gommoll, C. P., Chen, C., & Greenberg, W. M. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08197 · Cited by 83
Thorlund, K., Druyts, E., Wu, P., Balijepalli, C., Keohane, D., & Mills, E. (2015) · Journal of the American Geriatrics Society · doi:10.1111/jgs.13395 · Cited by 79
“Although some of the interventions exhibited statistical significance for efficacy and safety, clinical relevance of the statistical significance should be considered.(63) Sparse data on actual falls were found in the analysis.”
BackgroundMontgomery, S. A., Mansuy, L., Ruth, A., Bose, A., Li, H., & Li, D. (2013) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m08141 · Cited by 78
Self-citationMathews, M., Gommoll, C., Chen, D., Nunez, R., & Khan, A. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000057 · Cited by 77
Sleep deprivation as treatment for depression: systematic review and meta-analysis
Ioannou, M., Wartenberg, C., Greenbrook, J. T. V., Larson, T., Magnusson, K., Schmitz, L., Sjögren, P., Stadig, I., Szabó, Z., & Steingrimsson, S. (2021) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13253 · Cited by 75
Bauer, M., Dell’Osso, L., Kasper, S. F., Pitchot, W., Vansvik, E. D., Köhler, J., Jørgensen, L., & Montgomery, S. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.05.079 · Cited by 73
Self-citationPae, C.-U., Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Serretti, A. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140120 · Cited by 71
Bakish, D., Bose, A., Gommoll, C., Chen, C., Nunez, R., Greenberg, W. M., Liebowitz, M., & Khan, A. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130040 · Cited by 70
“For both doses of levomilnacipran ER, the treatment advantage versus placebo exceeded 2 points on the MADRS, suggesting that symptom improvement was clinically relevant.(22) Both doses of levomilnacipran ER compared with placebo also significantly reduced SDS total score from baseline, indicating that functional impro…”
BackgroundResultVortioxetine for depression in adults
Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011520.pub2 · Cited by 56
Croft, H. A., Pomara, N., Gommoll, C., Chen, D., Nunez, R., & Mathews, M. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m08992 · Cited by 61
Fava, M., Durgam, S., Earley, W., Lu, K., Hayes, R., Laszlovszky, I., & Németh, G. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000235 · Cited by 58
Brin, M. F., Durgam, S., Lum, A., James, L. M., Liu, J., Thase, M. E., & Szegedi, A. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000290 · Cited by 66
Wang, G., Gislum, M., Filippov, G., & Montgomery, S. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1014028 · Cited by 55
Self-citationSchilström, B., Konradsson‐Geuken, Å., Ivanov, V., Gertow, J., Feltmann, K., Marcus, M. M., Jardemark, K., & Svensson, T. H. (2011) · Synapse · doi:10.1002/syn.20853 · Cited by 54
Efficacy of escitalopram compared to citalopram: a meta-analysis
Montgomery, S., Hansen, T., & Kasper, S. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s146114571000115x · Cited by 52
Self-citationEsketamine Monotherapy in Adults With Treatment-Resistant Depression: A Randomized Clinical Trial
Janik, A., Qiu, X., Lane, R., Popova, V., Drevets, W. C., Canuso, C. M., Macaluso, M., Mattingly, G. W., Shelton, R. C., Zajecka, J. M., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1317 · Cited by 54
Möller, H.-J., Bitter, I., Bobes, J., Fountoulakis, K., Höschl, C., & Kasper, S. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.08.002 · Cited by 53
Self-citationBaghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Goodwin, G. M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Malt, U. F., Stein, D. J., et al. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0259-6 · Cited by 54
Self-citationKyle, P. R., Lemming, O. M., Timmerby, N., Søndergaard, S., Andreasson, K., & Bech, P. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000557 · Cited by 50
Deardorff, W. J., & Grossberg, G. T. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.960842 · Cited by 49
Approval of esketamine for treatment-resistant depression
Singh, J. B., Daly, E. J., Mathews, M., Fedgchin, M., Popova, V., Hough, D., & Drevets, W. C. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30533-4 · Cited by 46
Ochs-Ross, R., Wajs, E., Daly, E., Zhang, Y., Lane, R., Lim, P., Drevets, W. C., Steffens, D. C., Sanacora, G., Jamieson, C., et al. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.09.014 · Cited by 50
Levomilnacipran for the treatment of major depressive disorder: a review
Asnis, G. M., & Henderson, M. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s54710 · Cited by 46
What is the evidence for mirtazapine in treating cancer-related symptomatology? A systematic review
Economos, G. P. S., Lovell, N., Johnston, A., & Higginson, I. J. (2019) · Supportive Care in Cancer · doi:10.1007/s00520-019-05229-7 · Cited by 44
Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks
Gahr, M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12999140619122914 · Cited by 37
Huang, K., Lu, W., Wang, Y.-Y., Hu, G., Lu, C.-H., Lee, W., & Hsu, C. (2014) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414525837 · Cited by 41
Intranasal esketamine: From origins to future implications in treatment-resistant depression
Sanders, B. J., & Brula, A. Q. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.02.020 · Cited by 38
Chen, X., Hou, X., Bai, D., Lane, R., Zhang, C., Canuso, C., Wang, G., & Fu, D.-J. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s391096 · Cited by 35
“The average 2-point difference from placebo at endpoint in short-term studies has been used to establish the clinical relevance of an AD against placebo.(28,29) Although the first key secondary endpoint could not be formally evaluated due to the prespecified testing hierarchy, esketamine-treated patients experienced c…”
MethodDold, M., Bartova, L., & Kasper, S. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa034 · Cited by 34
“Moreover, the mean MADRS difference of intranasal esketamine is much higher than the 2-point difference suggested by Montgomery and Moller (2009) to consider an antidepressant-placebo separation to be clinically meaningful.”
BackgroundComparative efficacy of escitalopram in the treatment of major depressive disorder
Lam, R., & Ali (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12531 · Cited by 33
“Hence, some investigators have suggested that the MCID between two active agents should be half the drugplacebo MCID, corresponding to at least 1 point MADRS difference, or 5% response rate difference (number needed to treat = 20).(44) Using these MCID criteria, the superiority of escitalopram over citalopram and othe…”
BackgroundChristensen, M. C., McIntyre, R. S., Florea, I., Loft, H., & Fagiolini, A. M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000936 · Cited by 35
Jones, R., Freeman, M. P., Kornstein, S. G., Cooper, K., Daly, E., Canuso, C. M., & Nicholson, S. (2022) · Archives of Women s Mental Health · doi:10.1007/s00737-021-01185-6 · Cited by 34
Thase, M. E., Zhang, P. G. Y., Weiss, C., Meehan, S. R., & Hobart, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1638913 · Cited by 34
Adair, M., Christensen, M. C., Florea, I., Loft, H., & Fagiolini, A. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.074 · Cited by 31
Vilazodone in the treatment of major depressive disorder
Khan, A., Sambunaris, A., Edwards, J. G., Ruth, A., & Robinson, D. S. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000016 · Cited by 29
Montgomery, S., Gommoll, C., Chen, C., & Greenberg, W. M. (2014) · CNS Spectrums · doi:10.1017/s1092852914000273 · Cited by 27
Self-citationCastro, M., Wilkinson, S. T., Al Jurdi, R. K., Petrillo, M. P., Zaki, N., Borentain, S., Fu, D. J., Turkoz, I., Sun, L., Brown, B., et al. (2023) · CNS Drugs · doi:10.1007/s40263-023-01026-3 · Cited by 25
“For MADRS, response was defined as ≥50% improvement in total score from baseline, and remission was defined as a score ≤12 [19, 20].”
MethodPRO-DEMET Randomized Controlled Trial on Probiotics in Depression—Pilot Study Results
Gawlik-Kotelnicka, O., Margulska, A., Skowrońska, A., & Strzelecki, D. (2023) · Nutrients · doi:10.3390/nu15061400 · Cited by 27
Riesenberg, R. A., Yeung, P. P., Rekeda, L., Sachs, G. S., Kerolous, M., & Fava, M. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.22m14643 · Cited by 30
Trkulja, V. (2010) · Croatian Medical Journal · doi:10.3325/cmj.2010.51.61 · Cited by 28
Möller, H. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970903101665 · Cited by 25
Self-citationLam, R. W., Lönn, S. L., & Despiégel, N. (2010) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32833948d8 · Cited by 22
Saraceni, M. M., Venci, J. V., & Gandhi, M. A. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190013516504 · Cited by 22
A network meta-analysis of the dose–response effects of lurasidone on acute schizophrenia
Srisurapanont, M., Suttajit, S., Likhitsathian, S., Maneeton, B., & Maneeton, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-84836-z · Cited by 22
Jain, R., Chen, D., Edwards, J., & Mathews, M. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.855188 · Cited by 21
Mi, W., Di, X.-L., Wang, Y., Li, H., Xu, X., Li, L., Wang, H., Wang, G., Zhang, K.-R., Tian, F., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02435-0 · Cited by 22
Floden, L. L., Hudgens, S. A., Jamieson, C., Popova, V., Drevets, W. C., Cooper, K., & Singh, J. B. (2022) · CNS Drugs · doi:10.1007/s40263-022-00916-2 · Cited by 22
Diekamp, B., Borentain, S., Fu, D., Murray, R., Heerlein, K., Zhang, Q., Schüle, C., & Mathews, M. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s314874 · Cited by 18
One‐week escitalopram intake alters the excitation–inhibition balance in the healthy female brain
Zsido, R. G., Molloy, E. N., Čėsnaitė, E., Zheleva, G., Beinhölzl, N., Scharrer, U., Piecha, F. A., Regenthal, R., Villringer, A., Nikulin, V. V., et al. (2022) · Human Brain Mapping · doi:10.1002/hbm.25760 · Cited by 23
Montgomery, S., Mansuy, L., Ruth, A., Li, D., & Gommoll, C. (2013) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000009 · Cited by 17
Self-citationClinical benefits of vortioxetine 20 mg/day in patients with major depressive disorder
Christensen, M. C., McIntyre, R. S., Adair, M., Florea, I., Loft, H., & Fagiolini, A. M. (2023) · CNS Spectrums · doi:10.1017/s1092852923002249 · Cited by 15
Is there a risk of esketamine misuse in clinical practice?
Roncero, C., Torres, M. M., Szerman, N., Torrens, M., Vega, P., Andrés-Olivera, P., & Alvarez, E. (2025) · Therapeutic Advances in Drug Safety · doi:10.1177/20420986241310685 · Cited by 18
Getting the balance right: Established and emerging therapies for major depressive disorders
Vezmar (2010) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s10485 · Cited by 16
Laux, G. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_413-1 · Cited by 16
Kasper, S. F., Volz, H., Möller, H., Schläfke, S., Klement, S., Anghelescu, I., & Seifritz, E. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01783-2 · Cited by 12
Self-citationMartins-Correia, J., Fernandes, L. A., Kenny, R. P. W., Salas, B., Karmani, S. J., Inskip, A., Pearson, F., & Watson, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.06.099 · Cited by 11
Kornstein, S. G., Chang, C., Gommoll, C., & Edwards, J. G. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000217 · Cited by 11
Ouyang, Y., & Li, J. (2025) · Medicine · doi:10.1097/md.0000000000041495 · Cited by 10
Citrome, L., Gommoll, C., Tang, X., Núñez, R., & Mathews, M. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000056 · Cited by 11
Depressive Kernsymptome: Wirksamkeit medikamentöser antidepressiver Therapieverfahren
Damm, J., Eser, D., Schüle, C., Möller, H. ‐., Rupprecht, R., & Baghai, T. C. (2009) · Der Nervenarzt · doi:10.1007/s00115-008-2660-6 · Cited by 10
Self-citationLiu, Y., & Gu, X. (2011) · Wiley eBooks · doi:10.1002/9781118075647.ch8 · Cited by 8
How close is evidence to truth in evidence-based treatment of mental disorders?
Möller, H. (2011) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-011-0273-8 · Cited by 10
Self-citationXie, M., Qiu, Y., Wang, M., Wei, X., Tao, Y., Duan, A., Shang, J., Gao, W., & Wang, Z. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.02.018 · Cited by 9
Montgomery, S., Lyndon, G. J., Almas, M., Whalen, E., & Prieto, R. (2016) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000144 · Cited by 13
Self-citationComment to Drs Gastaldon, Papola, Ostuzzi and Barbui
Mathews, M., Daly, E. J., Popova, V., Heerlein, K., Canuso, C., & Drevets, W. C. (2020) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796020000268 · Cited by 7
“…relative to the comparator (a new oral antidepressant plus placebo nasal spray), with regard to the change in MADRS total score, which exceeded the mean difference that is considered clinically relevant in the psychiatric literature, namely 2.0 points or higher (Montgomery and Möller, 2009).”
InfluentialYasui‐Furukori, N., Tsuchimine, S., Kubo, K., Ishioka, M., Nakamura, K., & Inoue, Y. (2016) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000303 · Cited by 9
Kornstein, S. G., Gommoll, C., Chen, C., & Kramer, K. L. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.12.058 · Cited by 6
Specific effects of escitalopram on neuroendocrine response
Hawken, E. R., Owen, J. A., HUDSON, R. W., & Delva, N. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1633-1 · Cited by 6
Wang, L., Chen, X., Gu, X., Smedt, H. D., Popova, V., Fu, D., Canuso, C. M., Drevets, W. C., & Chen, G. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s417027 · Cited by 6
Hong, J. P., Malek, A. Z. A., Li, C., Paik, J., Sulaiman, A. H., Madriaga, G. O., Zhuo, J., Siggins, S., Fu, D., & Ju, P. (2023) · Asia-Pacific Psychiatry · doi:10.1111/appy.12548 · Cited by 5
Venable, K. E., Kelley, D. P., Jeansonne, A., Beyl, R. A., O’Bryan, S. M., Vatsavayi, V., Jones, S., Lee, C. C., & Francis, J. (2025) · Nutrients · doi:10.3390/nu17233720 · Cited by 5
Williamson, D. J., Nuechterlein, K. H., Tishler, T. A., Ventura, J., Ellingson, B. M., Turkoz, I., Keefe, R. S. E., & Alphs, L. D. (2022) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2022.100270 · Cited by 3
Filippova, N. V., Barylnik, Y. B., Shuldyakov, A. A., & Antonova, A. A. (2019) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2019119051154 · Cited by 2
Für jeden Patienten den optimalen Wirkstoff finden: Antidepressive Pharmakotherapie
Lieb, M., Rupprecht, R., & Baghai, T. C. (2012) · NeuroTransmitter · doi:10.1007/s15016-012-0565-x · Cited by 2
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_67 · Cited by 3
Efficacité de l’escitalopram et sévérité de la dépression : nouvelles données
Spadone, C. (2009) · L Encéphale · doi:10.1016/j.encep.2009.10.004 · Cited by 2
Kerr‐Gaffney, J., Zenasni, Z., Goldsmith, K., Yaziji, N., Jin, H., Colasanti, A., Geddes, J. R., Kessler, D. S., McAllister-Williams, H., Young, A. H., et al. (2025) · Health Technology Assessment · doi:10.3310/yqvf5347 · Cited by 1
Laux, G. (2017) · Springer eBooks · doi:10.1007/978-3-662-53697-1_11 · Cited by 1
▼Agomelatine for major depressive episodes
(2010) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2010.08.0043 · Cited by 1
Laux, G. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_413 · Cited by 4
Baghai, T. C., Möller, H. ‐., & Nitschmann, S. (2010) · Der Internist · doi:10.1007/s00108-010-2747-6
Self-citationDFP: Antidepressive Pharmakotherapie: Aktueller Stand und neue Entwicklungen
Baghai, T., Hp, V., & Hj, M. (2011) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Metadata
- Authors
- Montgomery, S. A., & Möller, H.-J.
- Affiliations
- University of London (GB)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Montgomery, Stuart A.
- Venue
- International Clinical Psychopharmacology
- Published
- 2009-05
- Volume
- 24
- Issue
- 3
- Pages
- 111-118
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2051198709
- Cited by
- 121
- References
- 22
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 3 · 2023: 11 · 2022: 4 · 2021: 10 · 2020: 6 · 2019: 7 · 2018: 3 · 2017: 4 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 15 · 2012: 1
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- escitalopram, antidepressants, clinical relevance, treatment effects, responder rate, remission, citalopram, paroxetine, duloxetine, depression, short-term treatment
- MeSH terms
- Depressive Disorder, Major, Major Depressive Disorder, Depressive Disorder, Humans, Psychiatric Status Rating Scales, Citalopram, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.